enGene Therapeutics Inc.

What they do

enGene develops genetic medicines delivered via its DDX gene delivery platform to mucosal tissues. Its lead candidate, detalimogene, is an intravesical gene therapy being studied for Bacillus Calmette-Guérin (BCG)-unresponsive non-muscle invasive bladder cancer (NMIBC) with carcinoma in-situ (CIS). The company has advanced detalimogene through pivotal clinical trials and plans to file a Biologics License Application (BLA) with the FDA in the second half of 2026.

Revenue drivers

• detalimogene (product candidate) — No approved products or revenue; potential commercial launch in the U.S. for BCG-unresponsive NMIBC with CIS, with BLA filing planned for 2H 2026.

Recent performance

In the six months ended April 30, 2026, enGene reported a net loss of $117.3 million for fiscal year 2025 and had cash, cash equivalents and marketable securities of $285 million as of the second quarter 2026. Interim data from the LEGEND pivotal Cohort 1 showed a 54% complete response rate (67/124) and a 3.2% rate of progression to muscle-invasive disease. The company reduced its workforce by approximately 50% in June 2026 to cut costs. No dividends have been paid.

Strategy

Management plans to file a BLA for detalimogene in 2H 2026, following FDA engagement on 12-month durability data from the LEGEND pivotal cohort. The company is also exploring a surfactant-enhanced formulation (detalimogene plus polidocanol rinse) to improve efficacy while preserving tolerability. To conserve cash, enGene stopped enrollment in additional LEGEND cohorts (2a, 2b, 3) and executed a 50% workforce reduction, focusing resources on BLA submission and pre-commercial activities. The company aims to commercialize detalimogene independently in the U.S. and selectively partner outside the U.S.

Risks

• Clinical and regulatory delays — FDA engagement and BLA submission depend on 12-month durability data from the LEGEND cohort, which are pending for 21 patients as of April 21, 2026.
• Cash burn and funding needs — Operating cash flow was negative $99.2 million in fiscal 2025, and the company may require additional capital to fund BLA filing and pre-commercial activities beyond its $285 million cash position.
• Operational execution risk — The 50% workforce reduction and halted cohort enrollment may impair the company's ability to advance its pipeline or retain key talent.
• Commercial adoption risk — detalimogene's success depends on integration into community urology practices and maintaining a tolerability profile that differentiates it from competitors; if the surfactant cohort shows added toxicity, it could undermine the strategy.

Outlook

Management expects to present 12-month complete response data from the LEGEND pivotal cohort and engage with the FDA in the second half of 2026 to discuss initiating a BLA submission for detalimogene before year-end. Additional cohorts are on hold pending FDA feedback. The company is prioritizing cash preservation to fund BLA and pre-commercial work.